Video Shorts

1:05
When Is IM Nailing vs Endoprosthetic Reconstruction the Right Choice in Metastatic Bone Disease?
7 months ago
by
R. Lor Randall, MD, FACS

0:30
Why Real-World Data Are Critical for Targeted Therapy Use in Cholangiocarcinoma
7 months ago
by
Lipika Goyal, MD

0:30
Unpacking Real-World Use of Relugolix in Prostate Cancer
7 months ago
by
Rana R. McKay, MD

0:34
Breaking Down the Basics of Orca-T and its Development
7 months ago
by
Sagar Patel, MD

1:00
Molecular Profiling Is Reshaping Treatment in Cholangiocarcinoma
7 months ago
by
Lipika Goyal, MD

0:55
Unpacking the Significance of the FDA Approval of Brexu-Cel for MCL
7 months ago
by
Lore Gruenbaum, PhD

0:57
Delineating Adjuvant Radiation Therapy Modalities for Breast Cancer
7 months ago
by
Meghan R. Flanagan, MD, MPH

1:11
The Evolution of Follicular Lymphoma Management
7 months ago
by
Amitkumar Mehta, MD

3:42
OncLive News Roundup for the Week of 3/29
7 months ago
by
Chris Ryan(+1 more)

0:29
Investigating ADT Plus Pembrolizumab in Salivary Gland Carcinoma
7 months ago
by
Manish R. Patel, DO

1:59
Unpacking the Meaning of Microplastics in Prostate Cancer Samples
7 months ago
by
Stacy Loeb, MD

0:51
Examining Real-World Outcomes With Lutetium Lu 177 Vipivotide Tetraxetan
7 months ago
by
Mohammad Arfat Ganiyani, MBBS

0:45
Will Neoadjuvant Therapy Reshape the Future of CRC Management?
7 months ago
by
Marc Lehrer Greenwald, MD

0:37
The Potential Role of the SERENA-6 Data in Breast Oncology
7 months ago
by
Kevin Kalinsky, MD, MS

0:48
HPV Prevention and Screening Gaps Continue to Drive Anal Cancer Risk
7 months ago
by
Richard Kim, MD

2:46
Luspatercept and Frontline Treatment Decisions in Lower-Risk MDS
7 months ago
by
Jan Bewersdorf, MD, FACP

3:08
OncLive News Roundup for the Week of 3/22
7 months ago
by
Chris Ryan(+1 more)

1:05
BOOM Provides Consensus on Periprosthetic Joint Infection Management in Orthopedic Oncology—but Evidence Gaps Remain
7 months ago
by
R. Lor Randall, MD, FACS

1:08
The Evolution of Axillary Lymph Node Dissection Practices in Breast Cancer
7 months ago
by
La-Urshalar Brock, FNP, BSN, MSN

1:45
What the FDA Approval of Daratumumab Plus Teclistamab Means for R/R Myeloma Care
7 months ago
by
Amrita Krishan, MD

1:20
Clinical Equipose When Recommending Individual Clinical Trials
7 months ago
by
Maurie Markman, MD

1:22
Robotics, Cost, and Caution: What’s Actually Advancing Surgical Care in CRC?
7 months ago
by
Marc Lehrer Greenwald, MD

1:13
Precision Medicine Remains the Priority During Multiple Myeloma Awareness Month
7 months ago
by
C. Ola Landgren, MD, PhD

1:22
Missed Signs and Screening Gaps: Why Is Early CRC Detection Falling Short?
7 months ago
by
Jeremy Kortmansky, MD

0:36
Elucidating the Next Steps After EV-Pembro in Urothelial Carcinoma
7 months ago
by
Georges Gebrael, MD

1:27
Exploring the Evolution of ctDNA Testing in Breast Cancer
7 months ago
by
Marla D. Lipsyc-Sharf, MD

0:22
PD-L1 As a Prognostic Biomarker in Penile Cancer
7 months ago
by
Chris Labaki, MD

0:46
Emphasizing the Importance of Considering Different Patient Priorities
7 months ago
by
Sami Diab, MD

0:56
Anal Cancer Care Is Entering a New Era of Precision Medicine and Immunotherapy Use
7 months ago
by
Richard Kim, MD

1:41
Examining Results From the ENVISION Trial in NMIBC
7 months ago
by
Sandip M. Prasad, MD
Advertisement
Advertisement
Trending on OncLive
1
Breast Cancer Experts Spotlight Practice-Informing and Thought-Provoking Data From ESMO 2026
2
TP53 Comutations, Long-Term Toxicity, and Sunvozertinib Access Shape EGFR+ NSCLC Treatment Decisions
3
Phase 1 Study of BGB-B2033 (GPC3 x 4-1BB Bispecific Antibody) Monotherapy: First Disclosure of Dose Optimization and Dose Escalation Update in Advanced Hepatocellular Carcinoma
4
Outpatient Models and Prophylactic Measures Help Bring Bispecifics Into Community Practice for R/R Myeloma
5
